Last reviewed · How we verify
NCT04661124
Evaluation of the Heidelberg Engineering SPECTRALIS With Flex Module for In-vivo Imaging in the Supine Position
trial testing SPECTRALIS in Retinal Disease in 88 participants. Completed in 22 April 2024.
17 September 2021
Quick facts
| Lead sponsor | Heidelberg Engineering GmbH |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 88 |
| Start date | 10 December 2020 |
| Primary completion | 17 September 2021 |
| Estimated completion | 22 April 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- SPECTRALIS
- SPECTRALIS with Flex Module
Conditions studied
- Retinal Disease — all drugs for Retinal Disease →
- Healthy Eyes — all drugs for Healthy Eyes →
Sponsor
Heidelberg Engineering GmbH
Who can join
22 and older, any sex, with Retinal Disease or Healthy Eyes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective clinical study conducted at one clinical site in the United States.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04661124
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Retinal Disease
Currently open trials in the same condition.
- NCT07149740 — Data Gathering for A10900 · recruiting
- NCT06852963 — A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Parti · Phase 1, PHASE2 · recruiting
- NCT05699096 — Perfluorooctyl Bromide Which Empowers the Liquid to Flat the Detached Retina and Displace the Underneath Fluids Anterior · recruiting
- NCT06289452 — Safety and Efficacy Study of IVB102 Injection in Subjects With X-linked Retinoschisis · EARLY_PHASE1 · active not recruiting
- NCT06520410 — Safety and Efficacy of 18 mm Short Vitrectomy Probe for Pediatric Vitreoretinal Surgeries · Phase 4 · recruiting
Other Heidelberg Engineering GmbH trials
Trials by the same sponsor.
- NCT07338461 — High Resolution Imaging OCT Study · NA · not yet recruiting
- NCT06397976 — The Heidelberg Engineering ANTERION Software Comparison Precision and Agreement Study · terminated
- NCT05051813 — The Heidelberg Engineering ANTERION Corneal Epithelium Thickness Precision and Agreement Study · completed
- NCT04961398 — Evaluation of Heidelberg Engineering SPECTRALIS OCT Signal to Noise Ratio Effect on Parameter Measurements · completed
- NCT04604002 — Evaluation of Additional Heidelberg Engineering SPECTRALIS With OCT Angiography Module (OCTA Module) Scan Types · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04661124 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Heidelberg Engineering GmbH
- Last refreshed: 15 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04661124.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing